Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely used breast cancer models. Here, we present an integrated map of the genome, transcriptome and immunome of 4T1. Results We found Trp53 (Tp53) and Pik3g to be mutated. Other frequently mutated genes in breast cancer, including Brca1 and Brca2, are not mutated. For cancer related genes, Nav3, Cenpf, Muc5Ac, Mpp7, Gas1, MageD2, Dusp1, Ros, Polr2a, Rragd, Ros1, and Hoxa9 are mutated. Markers for cell proliferation like Top2a, Birc5, and Mki67 are highly expressed, so are markers for metastasis like Msln, Ect2 and Plk1, which are known to be overexpressed in triple-negative breast cancer (TNBC). TNBC markers are, compared to a mammary gland control sample, lower (Esr1), comparably low (Erbb2) or not expressed at all (Pgr). We also found testis cancer antigen Pbk as well as colon/gastrointestinal cancer antigens Gpa33 and Epcam to be highly expressed. Major histocompatibility complex (MHC) class I is expressed, while MHC class II is not. We identified 505 single nucleotide variations (SNVs) and 20 insertions and deletions (indels). Neoantigens derived from 22 SNVs and one deletion elicited CD8+ or CD4+ T cell responses in IFNγ-ELISpot assays. Twelve high-confidence fusion genes were observed. We did not observe significant downregulation of mismatch repair (MMR) genes or SNVs/indels impairing their function, providing evidence for 6-thioguanine resistance. Effects of the integration of the murine mammary tumor virus were observed at the genome and transcriptome level. Conclusions 4T1 cells share substantial molecular features with human TNBC. As 4T1 is a common model for metastatic tumors, our data supports the rational design of mode-of-action studies for pre-clinical evaluation of targeted immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849 · cited 1×
“However, compared to the ERBB2 expression in the TCGA human breast cancer (BRCA) cohort, this value was on the lower end of the expression level spectrum [not shown9 and (61)].”
BackgroundNear-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723 · cited 1×
“Transcriptome Profiling Transcript abundance estimation was done with kallisto [(17); default options, version 0.”
MethodSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 3×
“1 mutations per MB, which is within the range observed for human breast cancer (31).”
BackgroundMethodResultPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626 · cited 1×
“Moreover, it is known that the Wnt/β-catenin (Ctnnb1) pathway plays an important role in human breast cancers (96) with high activation rates and association with a poor prognosis (97).”
BackgroundComprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256 · cited 2×
“We observed known breast cancer oncogenes Akt1 and Sf3b1 (36) with focal amplifications (copy number six and seven, respectively), while pan-cancer oncogene Myc had a copy number of 11 (Table S1).”
BackgroundThe clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 3×
“Of the most frequently mutated genes recently identified in breast cancer in general (41) and TNBC in particular (39) (Tp53,”
BackgroundResultMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819 · cited 1×
“For the testing of indelderived mutated peptides, mice (n = 3) were vaccinated with repetitive intravenous injections of 40 μg RNA lipoplexes (35) on days 0, 7, and 14.”
MethodSelf-citationMutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · cited 8×
“Indels were subjected to confirmation via Sanger sequencing [performed as in (34)] which left two of the three pre-filtered indels for further experiments.”
BackgroundMethodInfluentialSelf-citationMapSplice: Accurate mapping of RNA-seq reads for splice junction discovery
Wang, K., Singh, D., Zeng, Z., Coleman, S. J., Huang, Y., Savich, G. L., He, X., Mieczkowski, P., Grimm, S. A., Perou, C. M., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq622 · Cited by 1,193
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931 · cited 1×
“Differences in the absolute numbers in comparison to these reports might be due to genetic diversification of in vitro cell lines investigated at different laboratories at differing passage numbers (98) or different sequencing and mutation calling strategies.”
Pulaski, B. A., & Ostrand‐Rosenberg, S. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2002s39 · Cited by 912 · cited 2×
“4T1 can easily be transplanted into the mammary gland and was already described as poorly immunogenic, highly tumorigenic, invasive, and spontaneously metastasizing to distant organs (6).”
BackgroundKim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Haas, B. J., Dobin, A., Li, B., Stransky, N., Pochet, N., & Regev, A. (2019) · Genome biology · doi:10.1186/s13059-019-1842-9 · Cited by 646 · cited 1×
“Fusion Gene Detection Fusion genes were detected with an in-house pipeline: We employed the “wisdom of crowds” approach (23), and applied four fusion detection tools, SOAPFuse, MapSplice2, InFusion and STARFusion (23–26) to two technical replicates of the 4T1 cell line.”
MethodPatro, R., Mount, S. M., & Kingsford, C. (2014) · Nature Biotechnology · doi:10.1038/nbt.2862 · Cited by 586
Diouf, B., Cheng, Q., Krynetskaia, N. F., Yang, W., Cheok, M., Pei, D., Fan, Y., Cheng, C., Krynetskiy, E. Y., Geng, H., et al. (2011) · Nature Medicine · doi:10.1038/nm.2430 · Cited by 129 · cited 2×
“As the knockdown of PIK3C2B in human leukemia CCRF-CEM cells decreased sensitivity to 6TG in comparison to control (93), lacking or reduced expression of Pik3c2b mRNA in 4T1 might explain the resistance to 6TG treatment.”
Background
Cited by
Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment
Herdiana, Y., Wathoni, N., Shamsuddin, S., Joni, I. M., & Muchtaridi, M. (2021) · Polymers · doi:10.3390/polym13111717 · Cited by 196
Sarkar, R., Biswas, S., Ghosh, R., Samanta, P., Pakhira, S., Mondal, M., Dutta Gupta, Y., Bhandary, S., Saha, P., Bhowmik, A., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02518-0 · Cited by 69
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Kilian, M., Friedrich, M., Sanghvi, K., Green, E., Pusch, S., Kawauchi, D., Löwer, M., Sonner, J. K., Krämer, C., Zaman, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1881 · Cited by 18
Self-citation
Metadata
- Authors
- Schrörs, B., Boegel, S., Albrecht, C., Bukur, T., Bukur, V., Holtsträter, C., Ritzel, C., Manninen, K., Tadmor, A. D., Vormehr, M., Sahin, U., & Löwer, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-23
- Volume
- 10
- Pages
- 1195-1195
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3044173222
- Cited by
- 210
- References
- 19
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.